As biosimilars for innovator biologics advance, drug makers are seeking new indications for products in their portfolios as a means to protect their sales against oncoming—or existing—competition. This month saw 3 notable label developments for drugs made by Janssen, Alexion, and AbbVie.
As biosimilars for innovator biologics advance, drug makers are seeking new indications for products in their portfolios as a means to protect their sales against oncoming—or existing—competition. This month saw 3 notable label developments for drugs made by Janssen, Alexion, and AbbVie.
FDA grants a UC indication for ustekinumab
This week, Janssen announced that the FDA had granted approval for ustekinumab (Stelara) for the treatment of ulcerative colitis (UC).
Approval of the new indication was based on a phase 3 clinical study in which patients with UC received a single intravenous dose of ustekinumab, followed by a maintenance period in which they received subcutaneous ustekinumab treatment every 8 weeks for 44 weeks. In the induction phase, 19% of patients achieved remission by week 8, and in the maintenance period, 45% of patients were in remission—and 43% were in steroid-free remission—at 1 year.
The new indication for the interleukein-12 and -23 antagonist adds to a label that already contains the treatment of plaque psoriasis, psoriatic arthritis, and Crohn disease. The drug was also granted an indication for UC in the European Union in September.
Approval of the new indication comes shortly after biosimilar developer NeuClone announced that it has begun a phase 1 trial of its proposed ustekinumab biosimilar in Australia.
Alexion adds aHUS to ravulizumab’s label
The FDA gave rare disease drug maker Alexion a boost with approval of a new indication for its ravulizumab (Ultomiris), a success for to eculizumab (Soliris) that requires less frequent dosing. The drug is now approved to treat atypical hemolytic uremic syndrome (aHUS), a rare, progressive disease that can lead to irreversible organ damage and premature death.
Ravulizumab, which is administered every 8 weeks versus every 2 weeks for eculizumab, has already gained approval for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), and Alexion is studying the drug in patients with myasthenia gravis.
Alexion said earlier this year that it plans to “convert” its growing base of eculizumab users to ravulizumab as biosimilars of eculizumab approach.
Successor to Humira gets positive CHMP opinion
Finally, AbbVie’s successor to its brand-name adalimumab, Humira, the small-molecule Janus kinase inhibitor upadacitinib (Rinvoq), received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for an indication in rheumatoid arthritis (RA).
The drug maker is now awaiting a final decision from the European Commission, after which, the drug—which is also approved in the United States to treat RA—could help AbbVie to compete in a European RA landscape that now has multiple adalimumab biosimilars available.
While many health systems have reported substantial savings from switching patients to biosimilar adalimumab, upadacitinib could provide some advantages over the older adalimumab; in the SELECT-COMPARE study, upadacitinib outperformed both placebo and adalimumab in terms of the proportion of patients who achieved the American College of Rheumatology (ACR)’s criteria for 20% improvement at week 12 of treatment. The small-molecule drug was also superior to adalimumab in terms of the proportion of patients who reached ACR's criteria for 50% improvement at week 12, as well as in reduction of pain and improvement in quality of life as measured by the Health Assessment Questionnaire Disability Index.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.